Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

N-MOmentum study investigators

Research output: Contribution to journal › Article › peer-review

138 Scopus citations

Fingerprint

Dive into the research topics of 'Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences